[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Shih KK, Zhou QC, Aghajanian C, Huh J, Soslow RA, Morgan JC, Iasonos A, Chi DS, Barakat RR, Abu-Rustum NR: Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. Gynecol Oncol; 2010 Nov;119(2):270-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors.
  • OBJECTIVE: The objective of this study was to evaluate patterns of recurrence and prognostic factors as well as the role of adjuvant chemotherapy in stage II-IV ovarian SBT.
  • Progression-free survival (PFS) was defined as the time of diagnosis to time of recurrence/death or last follow-up.
  • The site of metastasis was pelvis in 15 patients (19%), omentum in 29 patients (36%), isolated lymph nodes in 2 patients (2.5%), lung in 1 patient (1%), axilla in 1 patient (1%), and multiple sites in 32 patients (40%).
  • With a median follow-up of 4.8 years, 17 patients (21%) developed recurrent disease.
  • Only patients with metastasis to the omentum or multiple sites developed recurrent disease.
  • Of the 65 stage III/IV patients, 17 patients (26%) received adjuvant chemotherapy following diagnosis.
  • The 3-year progression-free survival (PFS) was 89.9% (95% CI, 77.3-95.7) for patients who did not receive adjuvant chemotherapy compared with 70.6% (95% CI, 43.1-86.6) for patients who received adjuvant chemotherapy.
  • It is unclear from these data if adjuvant chemotherapy influenced PFS.
  • [MeSH-major] Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Neoplasm Recurrence, Local / pathology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20719369.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS774350; NLM/ PMC4843122
  •  go-up   go-down


2. Harris EE, Hwang WT, Seyednejad F, Solin LJ: Prognosis after regional lymph node recurrence in patients with stage I-II breast carcinoma treated with breast conservation therapy. Cancer; 2003 Nov 15;98(10):2144-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis after regional lymph node recurrence in patients with stage I-II breast carcinoma treated with breast conservation therapy.
  • BACKGROUND: The authors evaluated the risk factors for regional lymph node recurrence and the prognosis of patients with regional nodal recurrence after breast conservation therapy for Stage I-II breast carcinoma.
  • METHODS: Between 1977 and 1995, 1293 women with pathologic Stage I and II (T1-2, N0-1) breast carcinoma were treated with breast-conserving therapy including lumpectomy, axillary lymph node dissection, and definitive breast irradiation.
  • A total of 39 women (3%) had any regional lymph node recurrence.
  • RESULTS: Among 39 patients with a regional lymph node recurrence, 10 women had regional recurrence only, 16 had simultaneous locoregional recurrence, and 13 had simultaneous regional and distant recurrence.
  • Regional recurrence occurred in the axillary lymph nodes only (n = 21; 51%), supraclavicular lymph nodes only (n = 8; 23%), internal mammary lymph nodes only (n = 3; 8%), infraclavicular lymph nodes only (n = 3; 8%), or multiple lymph node sites (n = 4; 10%).
  • The median time to regional lymph node recurrence was 3.1 years (range, 0.2-20.9 years).
  • For patients who presented with simultaneous regional and distant metastases, the median survival period was 1.1 years, compared with 5.2 years for women who developed distant disease subsequent to regional recurrence.
  • CONCLUSIONS: Regional lymph node recurrence after breast conservation therapy may be salvaged, but is associated with a high rate of either simultaneous or subsequent distant metastatic dissemination and poor overall prognosis.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma / drug therapy. Carcinoma / pathology. Lymphatic Metastasis / pathology. Mastectomy, Segmental. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Salvage Therapy. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 14601083.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, Patterson BJ, Ferreri AJ, Ponzoni M, Devizzi L, Giardini R, Pinotti G, Capella C, Zinzani PL, Pileri S, López-Guillermo A, Campo E, Ambrosetti A, Baldini L, Cavalli F, International Extranodal Lymphoma Study Group: Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood; 2003 Apr 1;101(7):2489-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
  • A retrospective survey of patients with pathologically reviewed extragastric mucosa-associated lymphoma tissue (MALT) lymphomas from 20 institutions was performed.
  • Forty-one (23%) patients had involvement of more than one extranodal site at diagnosis and in 24 cases (13%) the lymphoma presented at multiple mucosal sites (9 of them with only mucosal involvement, without bone marrow or nodal disease).
  • Lymph node involvement was present in 21%.
  • Patients were treated with a variety of therapeutic strategies, including chemotherapy in 78 cases.
  • Our data confirm the indolent nature of nongastric MALT lymphomas and the high rate of patients presenting with disseminated disease, which, when limited to mucosal sites, was not associated with a poorer outcome.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cause of Death. Disease-Free Survival. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Staging / mortality. Neoplasms, Second Primary / mortality. Prognosis. Recurrence. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12456507.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Akimov MA, Gershanovich ML: [Clinical evaluation of the efficacy of modern first, second, and third line regimes of chemotherapy in patients with disseminated cutaneous melanoma]. Vopr Onkol; 2001;47(4):428-35
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical evaluation of the efficacy of modern first, second, and third line regimes of chemotherapy in patients with disseminated cutaneous melanoma].
  • The effectiveness and side-effects of various chemotherapy (CT) regimens were compared in 157 patients (74 males and 80 females, aged 23-79) with disseminated skin melanoma (DSM).
  • Most cases had multiple metastases to the skin and subcutaneous fat tissue, regional lymph nodes (59-69%), lung (14-38%) and liver (13-36%); to other sites--82 (52%).
  • DTIC was employed as first-line treatment in 71%.
  • DBDT (cisplatin, DTIC, BCNU, tamoxifen) was used in 42 patients: as first-line--13 (31%), second-line--21 (50%) and third-line (following the first two regimens in cases refractory to treatment or those with response-based evidence of tumor progression)--8 (19%).
  • Similar results were recorded in the group where 69% were given CT as second- and third-line treatment.
  • Combined treatment with prospidin+ CCNU + BCNU seems to offer more advantage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11710284.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


5. Hasuike Y, Takeda Y, Ueda S, Tujinaka T, Yoshida K: [A case report of primary hepatic carcinoid with lymph node metastasis--treatment of hepatic arterial infusion to post-reoperative liver and radiation to metastasis of para-aortic lymph nodes]. Gan To Kagaku Ryoho; 2002 Nov;29(12):2433-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of primary hepatic carcinoid with lymph node metastasis--treatment of hepatic arterial infusion to post-reoperative liver and radiation to metastasis of para-aortic lymph nodes].
  • She developed abdominal pain.
  • CT scans showed a low-density area in the lateral segment of the liver and lymph node swelling to the left of the abdominal aorta.
  • Unfortunately, the tumor recurred at multiple sites in the residual liver about 9 months after the first operation.
  • She underwent further liver resection and microwave coagulation therapy.
  • At that time, lymph node biopsy confirmed metastatic carcinoid.
  • We began hepatic arterial chemotherapy for the residual liver and radiation therapy for the para-aortic lymph nodes (total 45 Gy).
  • During chemotherapy, no recurrence was seen.
  • At 11 months after reoperation, however, multiple liver metastases occurred with severe liver dysfunction and jaundice.
  • [MeSH-major] Carcinoid Tumor / therapy. Liver Neoplasms / therapy. Lymphatic Metastasis / pathology
  • [MeSH-minor] Combined Modality Therapy. Doxorubicin / administration & dosage. Electrocoagulation. Female. Fluorouracil / administration & dosage. Hepatectomy. Humans. Infusions, Intra-Arterial. Microwaves / therapeutic use. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484093.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Tsavaris N, Kosmas C, Vadiaka M, Kontos A, Fotia M, Angelopoulou A, Vrizidis N, Soulla M, Sougioultzis S, Koufos Ch: Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study. Invest New Drugs; 2002 Feb;20(1):133-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study.
  • PURPOSE: To evaluate efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) failing multiple prior chemotherapy regimens (e.g.
  • METHODS: 20 patients with ACC; 13 males/7 females, median age 64 (range: 53-69), median Karnovsky PS: 80 (70-90), and sites of metastases; liver: 16, lung: 6, lymph nodes: 9, peritoneal: 8 and a life expectancy of at least 3 months, were entered in the present pilot study of Raltitrexed administration.
  • All patients had progressed after prior chemotherapy with 5-FU+LV and subsequently CPT-11, and some had received further infusional 5-FU, Raltitrexed was administered at a dose of 3 mg/m2 i.v. every 21 days.
  • Time-to-progression was 4.8 months (2.2-7) and survival 7.4 months (6.0-7.8).
  • CONCLUSION: Response to treatment with Raltitrexed is limited in patients with ACC failing multiple prior chemotherapy regimens, however, a limited percentage of patients with SD derived clinical benefit.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Colorectal Neoplasms / drug therapy. Enzyme Inhibitors / therapeutic use. Quinazolines / therapeutic use. Thiophenes / therapeutic use. Thymidylate Synthase / antagonists & inhibitors
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pilot Projects

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2943-52 [9738562.001]
  • [Cites] Ann Oncol. 1996 Nov;7(9):961-5 [9006748.001]
  • [Cites] Ann Oncol. 1996 Feb;7(2):179-82 [8777175.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):389-400 [8996166.001]
  • [Cites] Bull Cancer. 1998 Dec;Spec No:38-42 [9932083.001]
  • [Cites] Oncology (Williston Park). 1998 Aug;12 (8 Suppl 6):59-63 [9726093.001]
  • (PMID = 12003191.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Enzyme Inhibitors; 0 / Quinazolines; 0 / Thiophenes; EC 2.1.1.45 / Thymidylate Synthase; FCB9EGG971 / raltitrexed
  •  go-up   go-down


7. Yhim HY, Kang HJ, Choi YH, Kim SJ, Kim WS, Chae YS, Kim JS, Choi CW, Oh SY, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Lee JJ, Sung HJ, Kim HJ, Lee DH, Suh C, Kwak JY: Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer; 2010;10:321
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The breast is a rare extranodal site of non-Hodgkin lymphoma, and primary breast lymphoma (PBL) has been arbitrarily defined as disease localized to one or both breasts with or without regional lymph nodes involvement.
  • The patients with one extranodal disease in the breast (OED) with or without nodal disease were 49 (72.1%), and those with multiple extranodal disease (MED) were 19 (27.9%).
  • In multivariate analysis, MED (hazard ratio [HR], 3.61; 95% confidence interval [CI], 1.07-12.2) and fewer than four cycles of systemic chemotherapy with or without local treatments (HR, 4.47; 95% CI, 1.54-12.96) were independent prognostic factors for worse OS.
  • Twenty-five (36.8%) patients experienced progression, and the cumulative incidence of progression in multiple extranodal sites or other than breasts and central nervous system was significantly different between the OED group and the MED group (5-year cumulative incidence, 9.7 +/- 5.4% vs. 49.0 +/- 15.1%, p = 0.001).
  • CONCLUSIONS: Our results show that the patients included in OED group, reflecting different treatment outcome, prognosis and pattern of progression, should be considered as PBL in the future trial.
  • [MeSH-major] Breast Neoplasms / therapy. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Disease Progression. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Republic of Korea. Retrospective Studies. Time Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Ann Oncol. 2008 Jun;19 Suppl 4:iv77-80 [18519412.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):6-13 [11815954.001]
  • [Cites] J Surg Oncol. 2002 May;80(1):19-25; discussion 26 [11967901.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):131-9 [12488305.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):20-7 [12506165.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1173-8 [12916870.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Cancer. 1972 Jun;29(6):1705-12 [4555557.001]
  • [Cites] Cancer. 1978 Aug;42(2):693-707 [354774.001]
  • [Cites] Cancer. 1980 Jul 1;46(1):215-22 [7388763.001]
  • [Cites] Hematol Oncol. 1997 Feb;15(1):33-8 [9378471.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] Am J Clin Oncol. 1998 Aug;21(4):376-80 [9708637.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Oncology. 2005;69(3):256-60 [16166814.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4207-13 [16449523.001]
  • [Cites] Ann Surg. 2007 May;245(5):784-9 [17457172.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4930-5 [17299093.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1147-8 [17650450.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):233-41 [17932394.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2258-63 [18413640.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • (PMID = 20569446.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2927999
  •  go-up   go-down


8. Chen WJ, Kuo JY, Chen KK, Lin AT, Chang YH, Chang LS: Primary urothelial carcinoma of the ureter: 11-year experience in Taipei Veterans General Hospital. J Chin Med Assoc; 2005 Nov;68(11):522-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nephroureterectomy with bladder cuff excision was performed in 78 patients, 12 patients received segmental resection of the ureter, 4 received ureteroscopic laser coagulation, and 17 underwent chemotherapy or radiotherapy or both.
  • Disease recurrence in the nephroureterectomy group occurred in 36 patients (46.2%), with 17 (21.8%) at the urinary bladder, 2 (2.6%) at the retroperitoneum, 1 (1.3%) at the contralateral ureter, 6 (7.7%) with distant metastases to the lung, bone, distant lymph nodes or liver, and 10 (12.8%) at multiple sites.
  • Significant prognostic factors for cancer-specific survival by univariate analysis were pT (p = 0.00001), stage (p = 0.00001), type of treatment (p = 0.00001) and grade (p = 0.0001).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323396.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


9. Blanchard P, Plantade A, Pagès C, Afchain P, Louvet C, Tournigand C, de Gramont A: Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors. Gynecol Oncol; 2007 Jan;104(1):41-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors.
  • Isolated lymph node relapses (ILNR) are considered of relatively good prognosis with intensive therapy.
  • After initial optimal treatment, median progression-free survival (PFS) was 26 months.
  • Sites of relapse were retroperitoneum (n=15), left supraclavicular (n=7), mediastinum (n=4), iliac (n=4) and inguinal (n=3).
  • ILNR locations were unique in 63% of patients (n=17) and multiple in 37% (n=10).
  • Treatment modalities were surgery in eight patients (30%), chemotherapy in 15 (55%) and radiotherapy in 5 patients (18%), alone or in combination.
  • Time to relapse may not have its usual prognostic value.
  • Immediate or delayed therapy should be discussed in case of asymptomatic ILNR.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952391.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL: Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol; 2007 Jan;177(1):131-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection.
  • PURPOSE: We evaluated the recurrence pattern in patients with nonseminomatous germ cell tumors treated with post-chemotherapy retroperitoneal lymph node dissection and determined the optimal surveillance strategy in these patients.
  • MATERIALS AND METHODS: Between 1980 and 2003, 236 patients with clinical stage IIA-III nonseminomatous germ cell tumors underwent post-chemotherapy retroperitoneal lymph node dissection.
  • We retrospectively reviewed medical records for pertinent clinical and treatment related outcomes.
  • In our patient population recurrence developed in 45 (23%) patients and 22 (11%) died of disease at a median followup of 41 months (range 6 to 250) after retroperitoneal lymph node dissection.
  • Of the 45 patients with postoperative recurrence, 16 had concomitant multiple sites of recurrence with a total of 64 sites reported.
  • The most frequent site of recurrence was the chest (32, 49%), followed by the abdomen (14, 22%), supraclavicular lymph nodes (8, 13%), brain (5, 8%) and other sites (5, 8%).
  • CONCLUSIONS: Based on the recurrence pattern we propose stage specific surveillance guidelines for the followup of patients after post-chemotherapy retroperitoneal lymph node dissection.
  • [MeSH-major] Lymph Node Excision. Neoplasm Recurrence, Local / epidemiology. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / surgery. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162023.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. McMeekin DS, Tillmanns T: Endometrial cancer: treatment of nodal metastases. Curr Treat Options Oncol; 2003 Apr;4(2):121-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial cancer: treatment of nodal metastases.
  • Before the routine use of lymph node dissection, patients were presumed to have nodal disease based on imaging studies, palpation, and biopsy.
  • Although patients with nodal disease are uncommon, treatment of these patients poses multiple challenges.
  • It is our belief that unless nodes are surgically assessed, the clinician will not know whether the nodes are involved.
  • A thorough lymphadenectomy with removal of nodal tissue from multiple pelvic sites and from bilateral para-aortic regions is recommended for most patients with endometrial cancer.
  • Identification of positive nodes allows appropriate postoperative therapies to be used, and data support that nodal dissection may be therapeutic and prognostic.
  • Patients with positive nodes should receive radiation therapy directed to the nodal distribution, with patients having involved para-aortic nodes receiving an extended field.
  • The most promising treatment option is combination therapy with sequential radiation and chemotherapy.
  • Active chemotherapy agents in endometrial cancer are doxorubicin, cisplatin, and paclitaxel.
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Hysterectomy. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Oct;83(1):1-5 [11585406.001]
  • [Cites] Gynecol Oncol. 1991 Jan;40(1):55-65 [1989916.001]
  • [Cites] Gynecol Oncol. 1994 Oct;55(1):47-50 [7959265.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):348-56 [10684709.001]
  • [Cites] Gynecol Oncol. 1999 Nov;75(2):211-4 [10525373.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):273-8 [11330962.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(2):223-7 [1526859.001]
  • [Cites] Cancer. 1987 Oct 15;60(8 Suppl):2035-41 [3652025.001]
  • [Cites] Am J Obstet Gynecol. 1994 Jun;170(6):1677-81; discussion 1681-2 [8203425.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Gynecol Oncol. 2002 Feb;84(2):194-200 [11812074.001]
  • [Cites] Br J Cancer. 1997;75(12):1836-41 [9192991.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):4-9 [10502417.001]
  • [Cites] Gynecol Oncol. 1995 Jan;56(1):29-33 [7821843.001]
  • [Cites] Gynecol Oncol. 1995 Aug;58(2):189-93 [7622103.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):166-71 [2298404.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):498-503 [11520146.001]
  • (PMID = 12594938.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


12. Shibata N, Watari J, Satoh T, Tanabe H, Fujiya M, Yasuda A, Saitoh Y, Yokota K, Kohgo Y, Kino Y, Matsuda M, Kasai S: [Two cases of stage IV type 4 gastric cancer with good response to TS-1]. Gan To Kagaku Ryoho; 2002 Aug;29(8):1455-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of stage IV type 4 gastric cancer with good response to TS-1].
  • We report two patients with Type 4 gastric cancers having multiple lymph node metastasis and carcinomatosa which responded well to TS-1.
  • After administration of TS-1 orally for two courses, both patients showed improved extension of the gastric wall and almost complete reduction of metastatic lymph nodes.
  • In case 2, colonic stenosis due to peritonum carcinomatosa disappeared after chemotherapy with TS-1.
  • It was confirmed histopathologically that TS-1 was effective against the primary sites and lymph node metastasis.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Drug Administration Schedule. Drug Combinations. Female. Humans. Male. Middle Aged. Neoplasm Staging. Preoperative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12214477.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


13. Danforth DN Jr, Aloj L, Carrasquillo JA, Bacharach SL, Chow C, Zujewski J, Whatley M, Galen B, Merino M, Neumann RD: The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat; 2002 Sep;75(2):135-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: In women with breast cancer, knowledge of the local/regional extent of the tumor is essential for staging, treatment planning, monitoring response to therapy, and follow-up.
  • Positron emission tomography (PET) is an important imaging test which can detect tumor at multiple sites in women with breast cancer.
  • 18FDG uptake in the breast primary tumor, associated skin, axillary and internal mammary lymph nodes, and the contralateral breast was determined qualitatively, and correlated with histologic, clinical and radiographic findings.
  • Among stage I, II patients, the sensitivity for detection of the primary tumor was 83.3%, and for detection of axillary lymph node metastases was 42.9%.
  • 18FDG-PET was negative for the breast skin, contralateral breast, and internal mammary lymph nodes in all stage I, II patients, in agreement with clinical and radiographic findings.
  • Among 28 stage III, IV patients, the sensitivity of 18FDG-PET for detection of the primary tumor was 90.5%, and for detection of axillary lymph node metastases 83.3%.
  • Fourteen patients had clinically advanced changes in the skin, and the sensitivity of PET for detection of skin changes was 76.9%.
  • 18FDG-PET was positive in the internal mammary lymph nodes in 25.0%, and negative in the contralateral breast in all patients with stage III, IV breast cancer.
  • 18FDG-PET was studied in 10 patients following neoadjuvant chemotherapy, and showed a strong correlation with clinical response, and with clinical and pathological findings post-treatment at multiple local/regional sites.
  • 18FDG-PET may play a greater role in women with stage III, IV breast cancer because of increased sensitivity and the increased involvement of multiple local/regional sites with tumor.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lymph Nodes / radionuclide imaging. Tomography, Emission-Computed / methods
  • [MeSH-minor] Adult. Aged. Blood Glucose / metabolism. Female. Fluorine Radioisotopes. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Whole-Body Counting

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12243506.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Fluorine Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


14. Heidenreich A, Ohlmann C, Hegele A, Beyer J: Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol; 2005 Jan;47(1):64-71
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Repeat retroperitoneal lymph node dissection (RPLND) for the treatment of metastatic testicular cancer is an uncommonly performed procedure.
  • We evaluated the location, pathohistological results, postoperative complications and therapeutic outcome in 17 patients being referred for repeat RPLND after failure of the primary retroperitoneal approach.
  • RESULTS: All patients had nonseminomatous primaries with metastatic retroperitoneal lymph nodes; 4 and 14 patients had undergone primary RPLND and residual tumor resection (RTR), respectively, for metastatic testicular cancer.
  • Prior to repeat RPLND all patients had undergone 4 cycles of salvage chemotherapy for locoregional recurrences only with negative tumour markers at time of surgery.
  • Retroperitoneal recurrences were located at multiple sites: retrocaval area with infiltration of the vena cava, interaortocaval and paraaortic region, retrocrural space, suprahilar region, outfield metastases in the iliac region.
  • [MeSH-major] Germinoma / pathology. Germinoma / surgery. Lymph Node Excision. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Retroperitoneal Space. Retrospective Studies

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15582251.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


15. Hofmann U, O'Connor JP, Biyani CS, Harnden P, Selby P, Weston PM: Retroperitoneal metastatic squamous cell carcinoma of the tonsil (with elevated beta human chorionic gonadotrophin): a misdiagnosis as extra-gonadal germ cell tumour. J Laryngol Otol; 2006 Oct;120(10):885-7
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Head and neck cancers usually spread first to the regional lymph nodes but rarely may metastasize to distant sites.
  • Metastasis to distant lymph node groups is a rare event.
  • Furthermore, delayed multiple metastases without local recurrence is relatively uncommon.
  • A computed tomography scan demonstrated para-aortic retroperitoneal lymphadenopathy.
  • The patient underwent an open lymph node biopsy.
  • The initial pathological analysis was interpreted as extra-gonadal germ cell tumour and the patient received chemotherapy.
  • Following this, the chemotherapy regimen was changed; however, a restaging scan demonstrated progression, and the patient died from aspiration pneumonia secondary to alcohol intoxication.
  • This case highlights the necessity of using clinical, histological, immunohistological and ultrastructural examination to establish precise diagnosis and to avoid inappropriate treatment.
  • [MeSH-minor] Chorionic Gonadotropin, beta Subunit, Human / blood. Fatal Outcome. Humans. Hydronephrosis / complications. Male. Middle Aged. Neoplasm Proteins / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16716237.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Neoplasm Proteins
  •  go-up   go-down


16. Man S, Munoz R, Kerbel RS: On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis Rev; 2007 Dec;26(3-4):737-47
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.
  • It is well known clinically that advanced, bulky visceral metastatic disease is generally much less responsive to most anti-cancer therapies, compared to microscopic metastatic disease.
  • This problem is exacerbated when treating cancers that have been previously exposed to multiple lines of therapy, and which have acquired a 'refractory' phenotype.
  • However, mimicking such clinical treatment situations in preclinical mouse models involving the testing of new or existing cancer therapies is extremely rare.
  • Treatment of 'metastasis', in retrospect, usually involves minimal residual disease and therapy naïve tumors.
  • To that end, we have embarked on an experimental program designed to develop models of advanced, visceral metastatic disease, in some cases involving tumors previously exposed to various therapies.
  • Cell lines are established from such metastases and the process of orthotopic transplantation, surgical resection, and recovery of distant metastases is undertaken, at least one more time.
  • By waiting sufficient time after removal of the primary tumors, about only 1 month, mice with extensive metastatic disease in sites such as the lungs, liver, and lymph nodes can be obtained.
  • An example of therapy being initiated in an advanced stage of such disease development is illustrated.
  • Metastases that eventually stop responding to a particular therapy can be removed as a source of variant cell lines which have both 'refractory' and highly metastatic phenotypes.
  • Such models may provide a more accurate picture of the potential responsiveness to an experimental therapy so that a high degree of responsiveness observed could be a factor in deciding whether to move a particular therapy forward into phase I/phase II clinical trial evaluation.
  • An example of this is illustrated using doublet metronomic low-dose chemotherapy for the treatment of advanced metastatic breast cancer, using two conventional chemotherapy drugs, namely, cyclophosphamide and UFT, a 5-FU oral prodrug.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Disease Models, Animal. Neoplasm Metastasis / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Cyclophosphamide / therapeutic use. Drug Combinations. Humans. Mammary Neoplasms, Experimental / pathology. Mice. Mice, SCID. Neoplasm Transplantation. Tegafur / therapeutic use. Transplantation, Heterologous. Uracil / therapeutic use

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846863.001).
  • [ISSN] 0167-7659
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA41233
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 37
  •  go-up   go-down


17. Wang W, DO V, Hogg R, Wain G, Brand A, Bull C, Stenlake A, Gebski V: Uterine papillary serous carcinoma: patterns of failure and survival. Aust N Z J Obstet Gynaecol; 2009 Aug;49(4):419-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of the patients had platinum-based adjuvant chemotherapy and radiotherapy.
  • Sites of initial recurrence were documented.
  • Univariate and multivariate analysis was performed using Cox regression analysis to test the effects of multiple prognostic factors on survival.
  • The median OS was only 11 months if patients had macroscopic residual disease, and all patients died within 18 months despite adjuvant therapies.
  • The site(s) of initial recurrence were: vagina (five patients), pelvic lymph nodes (four patients), abdomen (11 patients), para-aortic lymph nodes (six patients), inguinal lymph nodes (two patients) and distant metastases in seven patients.
  • [MeSH-major] Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Serous / mortality. Neoplasm Recurrence, Local / pathology. Uterine Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Australia. Chemotherapy, Adjuvant. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Middle Aged. Multivariate Analysis. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Failure

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694700.001).
  • [ISSN] 1479-828X
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


18. Kayton ML, Meyers P, Wexler LH, Gerald WL, LaQuaglia MP: Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults. J Pediatr Surg; 2006 Jan;41(1):187-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults.
  • PURPOSE: Alveolar soft part sarcoma is a rare soft tissue neoplasm that can affect children and adolescents.
  • To define the clinical presentation, treatment, and outcome of young people with this rare sarcoma, we reviewed our clinical experience.
  • METHODS: After institutional review board approval, we examined the records of all patients younger than 25 years old who received treatment at our institution for alveolar soft part sarcoma in the past 30 years.
  • Demographics, tumor sizes, sites and extent of disease, treatments used, progression-free survival, and overall follow-up were evaluated.
  • Primary disease sites were thigh (n = 8), trunk (n = 6), retroperitoneum (n = 2), and scalp, neck, forearm, and calf (n = 1 each).
  • Metastatic sites included lymph nodes, lung, and brain.
  • Chemotherapy was used in 11 patients; radiation was used in 8.
  • We found an association between smaller tumor size and longer time to progression.
  • We were not able to demonstrate any benefit from chemotherapy or radiation.
  • Metastasectomies have been performed in multiple long-term survivors.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Disease Progression. Embolization, Therapeutic. Female. Follow-Up Studies. Humans. Male. Neoplasm Metastasis. Retrospective Studies. Survival Analysis. Treatment Outcome


19. Paramo JC, Summerall J, Poppiti R, Mesko TW: Validation of sentinel node mapping in patients with colon cancer. Ann Surg Oncol; 2002 Jul;9(6):550-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sentinel lymph node (SLN) mapping techniques have been validated in breast cancer and melanoma.
  • The first nodes highlighted with blue were identified as the SLNs.
  • SLNs underwent multiple sectioning and immunohistochemical staining for cytokeratin.
  • In 9 of 45 cases (20%), the SLNs were the only sites of metastases.
  • Negative SLNs accurately predict the status of non-SLNs 97% of the time.
  • Eleven percent of patients were upstaged by demonstration of micrometastases and may benefit from adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Sentinel Lymph Node Biopsy / education. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Prognosis. Prospective Studies. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2002 Jul;9(6):529-31 [12095966.001]
  • (PMID = 12095970.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Nguyen CV, Falcón-Escobedo R, Hunt KK, Nayeemuddin KM, Lester TR, Harrell RK, Bassett RL Jr, Gilcrease MZ: Pleomorphic ductal carcinoma of the breast: predictors of decreased overall survival. Am J Surg Pathol; 2010 Apr;34(4):486-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We identified 37 cases of pleomorphic carcinoma of the breast and evaluated the association between clinical outcome and multiple clinicopathologic features.
  • Patients with invasive pleomorphic lobular carcinoma and those without at least a tissue biopsy before chemotherapy were excluded.
  • As the morphologic features of pleomorphic carcinoma can be seen in primary tumors from other sites, it is important to recognize this tumor as a rare variant of invasive breast carcinoma.
  • [MeSH-minor] Adult. Aged. Cell Nucleus / pathology. Female. Giant Cells. Humans. Lymph Nodes / pathology. Mastectomy. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Texas / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154588.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Gauerke S, Driscoll JJ: Hidradenocarcinomas: a brief review and future directions. Arch Pathol Lab Med; 2010 May;134(5):781-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These neoplasms can derive from preexisting clear cell hidradenomas but more commonly appear de novo, with the molecular events responsible for the pathogenesis currently unknown.
  • Historically, diagnosis has been difficult because of the few cases, inconsistent nomenclature, variable morphology of cells that compose the neoplasm, and confusion with other visceral metastatic tumors.
  • Presentation is generally benign with an indolent clinical course that typically includes local and multiple recurrences.
  • Despite wide-excision surgery, disease at regional lymph nodes and metastatic sites is common and linked to decreased survival.
  • Currently, molecular markers of pathogenesis as well as effective forms of adjuvant chemotherapy are lacking.
  • Future studies are required to identify the histopathologic and immunohistochemical features, which may facilitate diagnosis and foster development of molecularly targeted forms of adjuvant therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20441512.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


22. Hayase E, Kurosawa M, Yonezumi M, Suzuki S, Suzuki H: Aggressive sporadic histiocytic sarcoma with immunoglobulin heavy chain gene rearrangement and t(14;18). Int J Hematol; 2010 Nov;92(4):659-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histiocytic sarcoma (HS) is a rare but aggressive malignant neoplasm of histiocytic lineage with a poor prognosis.
  • HS was diagnosed according to morphologic and immunohistochemical features observed on biopsy of the left inguinal lymph node.
  • Positron emission tomography showed disseminated areas of increased 18F-fluorodeoxyglucose uptake in multiple lymph nodes, the liver, spleen, both lungs, both kidneys, and many bony sites.
  • The patient received localized irradiation therapy followed by chemotherapy, she failed to respond and died of the disease progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Immunol. 2007 May;8(5):463-70 [17440452.001]
  • [Cites] Nature. 2007 Sep 27;449(7161):473-7 [17851532.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1950-5 [12406913.001]
  • [Cites] Am J Hematol. 2007 Oct;82(10):932-3 [17617785.001]
  • [Cites] Histopathology. 2002 Jul;41(1):1-29 [12121233.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1406-11 [8898846.001]
  • [Cites] Am J Surg Pathol. 2009 Jun;33(6):863-73 [19145200.001]
  • [Cites] Ann Nucl Med. 2008 Oct;22(8):715-7 [18982475.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):617-24 [15832085.001]
  • [Cites] Mod Pathol. 2005 May;18(5):693-704 [15696128.001]
  • [Cites] Diagn Pathol. 2007 Feb 26;2:7 [17324277.001]
  • [Cites] Int J Hematol. 2009 May;89(4):529-32 [19343479.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5433-9 [18272816.001]
  • [Cites] Leuk Lymphoma. 2010 May;51(5):802-12 [20331331.001]
  • [Cites] Cancer. 1995 Aug 15;76(4):609-17 [8625154.001]
  • [Cites] Cell. 2004 May 28;117(5):663-76 [15163413.001]
  • [Cites] Pediatrics. 2005 Aug;116(2):e322-5 [16024682.001]
  • [Cites] Int J Hematol. 2004 Nov;80(4):365-9 [15615263.001]
  • [Cites] Intern Med. 2008;47(3):165-9 [18239326.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1133-44 [15316312.001]
  • [Cites] J Hematop. 2009 May 09;2(3):135-41 [19669194.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):248-50 [15050956.001]
  • (PMID = 20976632.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Prakash S, Sarran L, Socci N, DeMatteo RP, Eisenstat J, Greco AM, Maki RG, Wexler LH, LaQuaglia MP, Besmer P, Antonescu CR: Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol; 2005 Apr;27(4):179-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All five pediatric GISTs occurred in girls, involved the stomach as multiple nodules, showed predominantly an epithelioid morphology, often involved lymph nodes, and lacked KIT or PDGFRA mutations.
  • Although all five patients developed recurrence (four in the liver, three in the peritoneum, and two in both sites), four are still alive with disease.
  • Of the 10 GISTs in young adults, half occurred in the small bowel and had spindle cell morphology, and one case had lymph node metastasis.
  • Seven patients developed recurrence, and at last follow-up two patients had died of disease.
  • GISTs that occur in children are a separate clinicopathologic and molecular subset with predilection for girls, multifocal gastric tumors, and wild-type KIT/PDGFRA genotype.
  • In contrast, GISTs in young adults are a more heterogeneous group, including cases that resemble either the pediatric or the older adult-type tumors.
  • The distinct gene expression profile suggests avenues for investigation of pathogenesis and potential therapeutic strategies.
  • [MeSH-minor] Adolescent. Adult. Amino Acid Sequence. Antineoplastic Agents / therapeutic use. Benzamides. Child. DNA Mutational Analysis. Female. Gene Expression Profiling. Humans. Imatinib Mesylate. Male. Molecular Sequence Data. Neoplasm Recurrence, Local / drug therapy. Oligonucleotide Array Sequence Analysis. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use. Sequence Homology, Amino Acid

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838387.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102774; United States / NCI NIH HHS / CA / CA94503; United States / NHLBI NIH HHS / HL / HL/DK55748; United States / NCI NIH HHS / CA / P01 CA 47179-10A1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Number-of-references] 39
  •  go-up   go-down






Advertisement